Entrepreneurship & Innovation for Leber’s Congenital Amaurosis (E&ILCA) started in January 2016. Lead by the strong desire to reach to every rare disease patient affected by Leber’s Congenital Amaurosis, E&ILCA takes responsibility to provide access to information about treatments for patients, regardless of their location in the world. E&ILCA is a non-profit enterprise focused on improving family life for those suffering from LCA. E&ILCA's main focus are cutting-edge technologies, advancing translational sciences & global liaising for genetically caused blindness. To integrate patient-centric research with scientific expertise, E&ILCA leads in the proactive establishment of communication between global stakeholders. E&ILCA initiates and fosters vast networks of top life-science clusters and most influential groups, including physicians, insurance, patient advocacy organizations, national health institutes, investment associates, governments, and academics. With the use of numerous social-media platforms, virtual conferences, local scientific events, national symposia and international conferences, E&ILCA raises public awareness & educates about the needs of rare disease patients. E&ILCA successfully created and implemented unconventional and innovative ways to engage the general public.